How India Exports Glibenclamide to the World

In the United States, glibenclamide is approved for the treatment of type 2 diabetes mellitus. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for glibenclamide, indicating a well-established generic market. Notably, the FDA has not issued any import alerts specifically targeting glibenclamide from India, suggesting compliance with U.S. regulatory standards.

Given the presence of 194 active Indian exporters and 335 buyers, with a repeat buyer rate of 48.1%, the U.S. market remains a viable destination for Indian glibenclamide exports. However, exporters must ensure adherence to FDA regulations, including Good Manufacturing Practices (GMP) and accurate labeling, to maintain market access.

In the European Union, glibenclamide has been authorized for the treatment of neonatal diabetes mellitus under the brand name Amglidia. The European Medicines Agency (EMA) granted marketing authorization for Amglidia on May 24, 2018, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in February 2018. This authorization underscores the importance of glibenclamide in managing specific forms of diabetes within the EU.

The United Kingdom, having exited the EU, continues to recognize EMA approvals through the Medicines and Healthcare products Regulatory Agency (MHRA). Therefore, glibenclamide remains authorized for use in the UK under the same conditions. Exporters targeting these markets must comply with EU and UK GMP requirements, ensuring product quality and safety.

Glibenclamide is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its significance in global health. This inclusion facilitates its adoption in various national formularies and supports its availability in low- and middle-income countries.

The drug is also recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is crucial for exporters to ensure acceptance in international markets.

In India, glibenclamide is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. As of the latest notification, the ceiling price for glibenclamide was set in March 2025. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for exporting pharmaceutical products, ensuring compliance with national regulations.

The primary patents for glibenclamide have expired, leading to a robust generic market. This expiration allows multiple manufacturers to produce and export the drug, contributing to competitive pricing and widespread availability.

In June 2025, the NPPA revised the ceiling price for glibenclamide, reflecting changes in production costs and market dynamics. This adjustment aims to balance affordability for patients and sustainability for manufacturers.

In September 2025, the EMA updated its guidelines on GMP for active pharmaceutical ingredients (APIs), emphasizing stricter quality controls. Indian exporters must align with these updated standards to maintain access to the European market.

In December 2025, the WHO included glibenclamide in its updated Model List of Essential Medicines, reaffirming its importance in global diabetes management strategies.

In February 2026, the FDA issued a guidance document on the labeling requirements for generic drugs, including glibenclamide. This guidance aims to ensure consistency and clarity in drug information for healthcare providers and patients.

In March 2026, the Indian Ministry of Health and Family Welfare announced a policy initiative to streamline the export NOC process for pharmaceuticals, potentially reducing administrative burdens for exporters.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape, necessitating continuous monitoring and compliance by exporters to maintain market access and competitiveness.

Glibenclamide, a widely used antidiabetic medication, relies on Active Pharmaceutical Ingredients (APIs) that are predominantly manufactured in India. However, the production of these APIs is heavily dependent on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This dependency exposes the Indian pharmaceutical industry to potential supply chain disruptions stemming from geopolitical tensions, trade policy changes, or production issues within China.

In recent years, India has initiated efforts to reduce its reliance on Chinese imports for critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to manufacture essential molecules like Penicillin G, 6-APA, and Clavulanic Acid. These initiatives are part of a broader strategy to bolster domestic production and decrease import dependence by half. Despite these efforts, the transition to self-sufficiency is gradual, and the industry remains vulnerable to external supply chain shocks in the interim.

Analysis of TransData Nexus's proprietary trade data reveals a low supplier concentration in the export of Glibenclamide from India. The top five exporters collectively account for only 3.6% of the total export value, with the leading exporter, MEDOPHARM, holding a mere 1.0% share. This dispersion suggests a diversified supplier base, mitigating risks associated with over-reliance on a single source.

The Indian government's PLI scheme, launched to incentivize domestic production of APIs and KSMs, has seen significant investment commitments. By November 2025, the scheme had attracted investments exceeding ₹4,570 crore, surpassing initial targets. While these developments are promising, the full impact on reducing supplier concentration and enhancing supply chain resilience will materialize over time.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Any geopolitical instability in these regions can lead to delays and increased costs. Additionally, ongoing US-China trade tensions have the potential to disrupt the supply of KSMs essential for Glibenclamide production.

Regulatory agencies have been proactive in addressing potential shortages. In February 2026, the European Medicines Agency (EMA) published a statement on behalf of the Drug Shortages Global Regulatory Working Group, emphasizing collaborative strategies to mitigate drug shortages through enhanced transparency and proactive risk assessments. While no specific shortage alerts for Glibenclamide have been issued recently, the interconnected nature of global supply chains necessitates continuous monitoring to preemptively address potential disruptions.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to bolster domestic manufacturing capabilities for APIs and KSMs.

• Enhance Supplier Collaboration: Foster closer relationships with a broader range of suppliers to ensure flexibility and responsiveness in the event of disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains, enabling proactive risk management.

• Implement Robust Inventory Management: Maintain strategic stockpiles of critical materials and finished products to buffer against short-term supply disruptions.

RISK_LEVEL: MEDIUM